Torrent Pharmaceuticals Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Torrent Pharmaceuticals Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Tangible Net Worth Ratio: Goodwill and other intangibles are larger than its whole net worth, so its tangible net worth is negative. Less tangible than almost all Healthcare companies in India.
- Tangible Assets Ratio: Of every ₹100 the company owns, ₹36 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. Less tangible than 98% of Healthcare companies in India.
- Self-Funding Ratio: Over the last 3 years its own operating cash covered its investment spending (capex) 5.2 times. Higher than 92% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹155Over the last 3 years, every ₹100 of reported profit came with ₹155 of operating cash.
Higher than 72% of Healthcare companies in India.
Self-Funding Ratio
5.2×Over the last 3 years its own operating cash covered its investment spending (capex) 5.2 times.
Higher than 92% of Healthcare companies in India.
Cash Locked Ratio
₹22For every ₹100 of sales, ₹22 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹22 tied up three years earlier.
Less money tied up than 54% of Healthcare companies in India.
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 83% of Healthcare companies in India.
Growth Efficiency Ratio
₹21Sales grew 45% in 3 years; of every extra ₹100 of sales, ₹21 became extra profit.
Higher than 66% of Healthcare companies in India.
Asset Productivity Ratio
+45% / +195%In 3 years sales changed by +45% while total assets changed by +195%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
1.0×Debt due within a year is covered 1.0 times by its yearly operating cash.
Lower than 53% of Healthcare companies in India.
Cash Cushion Ratio
−7%Debt, after subtracting cash, equals 7% of its market value (net debt).
Lower than 71% of Healthcare companies in India.
Tangible Assets Ratio
36%Of every ₹100 the company owns, ₹36 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 98% of Healthcare companies in India.
Tangible Net Worth Ratio
NegativeGoodwill and other intangibles are larger than its whole net worth, so its tangible net worth is negative.
Less tangible than almost all Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Torrent Pharmaceuticals Limited owes ₹0.60 for every ₹1 it owns. Net profit rose 13% in the year to Mar 2026, and grew 20% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
73.7Investors pay ₹73.7 for every ₹1 of Torrent Pharmaceuticals Limited's yearly profit, higher than 83% of Healthcare companies in India.
P/B ratio
20.93The share price is 20.93 times Torrent Pharmaceuticals Limited's book value per share, higher than almost all Healthcare companies in India.
Market cap
₹175,551 CrThe total market value of all of Torrent Pharmaceuticals Limited's shares at today's price (share price × number of shares), larger than almost all Healthcare companies in India. PosiCap size class: Tito Cap.
Net worth (book value)
₹8,388 CrWhat Torrent Pharmaceuticals Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹220.53Net worth divided by the number of shares. The share price of ₹4,615 is 20.9 times this, which is the P/B above.
Return on equity (ROE)
25.3%Torrent Pharmaceuticals Limited earned 25.3% on its shareholders' money over the last year, higher than 88% of Healthcare companies in India.
Owes vs Owns
0.60×Torrent Pharmaceuticals Limited owes ₹0.60 for every ₹1 it owns (moderate), higher than 91% of Healthcare companies in India.
Dividend yield
0.82%Torrent Pharmaceuticals Limited pays 0.82% of its share price as dividends a year, higher than 76% of dividend-paying Healthcare companies in India.
Revenue growth
+22%Revenue rose 22% in the year to Mar 2026, and grew 13% a year on average over 3 years.
Profit growth
+13%Net profit rose 13% in the year to Mar 2026, and grew 20% a year on average over 3 years.
Profit margin
15.7%Torrent Pharmaceuticals Limited keeps ₹16 of every ₹100 of revenue as net profit.
Cash quality
1.4×Cash from Torrent Pharmaceuticals Limited's business was 1.4× its reported profit in the year to Mar 2026 — its profit turned into cash.
Interest cover
8.9×Torrent Pharmaceuticals Limited's operating profit covered its interest costs 8.9 times in the year to Mar 2026.
Cash vs debt
Net debtTorrent Pharmaceuticals Limited had ₹12,670 Cr more debt than cash (net debt) at Mar 2026.
Questions
What is Torrent Pharmaceuticals Limited's P/E ratio?
Investors pay ₹73.7 for every ₹1 of Torrent Pharmaceuticals Limited's yearly profit, higher than 83% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Torrent Pharmaceuticals Limited: ₹175,551 Cr ÷ ₹8,388 Cr (31 Mar 2026) = 20.9.
What is Torrent Pharmaceuticals Limited's return on equity?
Torrent Pharmaceuticals Limited earned 25.3% on its shareholders' money over the last year, higher than 88% of Healthcare companies in India.
How much does Torrent Pharmaceuticals Limited owe compared with what it owns?
Torrent Pharmaceuticals Limited owes ₹0.60 for every ₹1 it owns (moderate), higher than 91% of Healthcare companies in India.
Does Torrent Pharmaceuticals Limited pay a dividend?
Yes. Torrent Pharmaceuticals Limited pays 0.82% of its share price as dividends a year, higher than 76% of dividend-paying Healthcare companies in India.
Is Torrent Pharmaceuticals Limited's revenue growing?
Revenue rose 22% in the year to Mar 2026, and grew 13% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.